anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is dietary nutritional supplements in the form of pellets and method of preparation thereof. The pellet composition comprises the nutritional supplements protein-milk protein, Soya protein; amino acid L-Lycine; carbohydrate-sucrose, Malto Dextrine, Cocoa powder; fats; Vitamin-Vitamin A from natural source of mixed Carotenoids, Cynocobalmine, Vitamin D3, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin C, Vitamin E, Vitamin K, Folic Acid, Calcium Pantothenate, Niacinamide; minerals-Calcium, Phosphorous, Carbonyl Iron, Magnesium, Manganese, Copper, Zinc, Chromium, Selenium; permitted food colour and flavour. All the ingredients are crushed in uniform powder and coated on sugar pellets containing lactose by loading/spraying method, drying & sieving the pellets and amending in double cone blender. This is more stable form and easily eat with/without milk/water. On dispersion in milk or water, it does not form lumps. Pellet composed of dietary nutritional supplements gives synergistic effect and adds nutritional value to an individual.
In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS\>60-70. Discretionary use of intrathecal morphine may be used.
1. Technical Result Simplification of technological process and reduce of net cost. 2. Essence The preparation is manufactured by mixing water and amphiphilic component selected from the group of organic sulfates and organic sulfonates, at least one antibiotic components from the group of lincosamide, aminoglycoside and tetracycline, an organic auxiliary component and/or an inorganic auxiliary component and if need be at least one biologically active component and if need be subsequent shaping into molded elements, granulates, powders, foils, shaped masses and threads. The obtained antibiotic preparation is used as an implant or coating thereof. 3. Field of Application Medicine, veterinary.
Transition from epoprostenol to treprostinil injection is accomplished by initiating the infusion of treprostinil injection and increasing it, while simultaneously reducing the dose of intravenous epoprostenol. The transition to treprostinil injection should take place in a hospital with constant observation of response (e.g., walk distance and signs and symptoms of disease progression). 

Initiate treprostinil injection at a recommended dose of 10% of the current epoprostenol dose, and then escalate as the epoprostenol dose is decreased (see Table 2 for recommended dose titrations).

Patients are individually titrated to a dose that allows transition from epoprostenol therapy to treprostinil injection while balancing prostacyclin-limiting adverse events. Treat increases in the patient’s symptoms of PAH first with increases in the dose of treprostinil injection. Treat side effects normally associated with prostacyclin and prostacyclin analogs first by decreasing the dose of epoprostenol.
Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention discloses a capsule polyurethane drug controlled release body with a temperature control switch. The capsule polyurethane drug controlled release body is prepared by loading the drug by a temperature-sensitive polyurethane capsule pipe. In the application of the capsule polyurethane drug controlled release body, a drug release characteristic with temperature response is expressed; and an 'open-close' effect is present. The capsule wall polyurethane molecules are in a rigid crystalline state below the switch temperature, so that diffusion and release of the drug in the controlled release body are blocked; when the temperature rises to higher than the switch temperature, the polyurethane molecules are in a molten state, so that the drug in the body migrates to the capsule wall and the capsule wall drug release outward continuously, with the concentration as a mass ladder force. Besides, the special design of the capsule wall can realize ideal drug diffusion capacity. The invention also discloses a preparation method of the capsule polyurethane drug controlled release body. The temperature-sensitive polyurethane capsule pipe of the drug controlled release body and unsymmetrical structure of the capsule wall design makes the drug controlled release body have fast temperature response speed, good repeatability of the drug release switch, freely adjustable drug release amount, capacity of uniform drug release, no physiological toxicity, so that the drug controlled release body has wide application prospects in clinic local drug treatment.
Subjects will be randomly assigned to two groups: an eccentric only resistance training group or an eccentric training plus blood flow restriction group. Subjects will train at a moderately low intensity on a multiple-joint eccentric device. Those in the blood flow restriction will wear blood flow restriction cuffs on their upper thighs to reduce blood flow during the brief protocol. The training session will occur twice per week and will last \~5 minutes, including a one minute warm up, a one minute cool down and a three minute workout phase. The training program will last 7 weeks. Testing will be conducted at baseline (following a one session familiarization), 4 weeks and after the end of the 7 week training period. Assessments will focus on muscle strength, function, and morphology (size).
Most children experience postoperative pain after major abdominal surgery. They may have ineffective ventilation, following atelectasis and pneumonia if receive inadequate pain management. There are several methods used for pain relief such as epidural block, intravenous analgesia with local infiltration, transversus abdominis plane (TAP) block by ultrasound guided and surgical TAP block. Therefore, the investigators would like to compare the effectiveness of postoperative pain control with TAP block. However, TAP block in children need experience and ultrasound. The investigators decided to do surgical TAP block performing by inject from peritoneum point to skin instead.
mothers of children with autistic spectrum disorders have a lots of burdens due to child symptoms its, lack of availability of services and limited resources , thus in turn lead them to become unable to face problems/stressors and to be psychological distress. CBT is an effective therapy to minimize stress, anxiety and depression. Mothers who participated in the study recruited from three governmental hospitals that has an out patients clinics specialized in autism and other developmental disorders for children at ElBehairah governate , Egypt . Based on inclusion and exclusion criteria for mothers and their children, mothers informed about the nature of the study and their benefits for participations. assessment tools will use ; depression ,anxiety and stress scale (DAS) and problem solving inventory (PSI). First assessment will occur , then randomly the participants divide into either study ( intervention) group or control group .CBT sessions will provide for study group to enhance their problem solving ability and psychological state. Second assessment (T2) will occur after finishing program sessions for all participants
An equine or canine immunomodulating composition comprises a pre-packaged, feed supplement comprising effective amounts of a beta-glucan mixture which is at least 60 percent purified. The feed supplement may be a dry feed supplement further including (b) an effective amount of at least one flavoring, and (c) an effective amount of a sweetener. The feed supplement may include an effective amount of an antioxidant; and an effective amount of an emulsifier. An alternative composition further comprises an appetite stimulant. A method of treating equine or canine microbial infections following the diagnosis of a microbial infection comprises the step of treating the equine or canine for a period at least long enough to prevent immediate recurrence of the microbial infection with effective amounts of the immunomodulating composition described above. The immunomodulating composition may alternatively be used in combination with an effective amount of an antibiotic.
Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
BACKGROUND AND OBJECTIVES: In virtual surgery, the resolution of bleeding surface has a significant impact on the realism. The computational complexity of internal particles reduces real-time performance, which has no obvious contribution to the visual effect of simulation. This paper focuses on the study of bleeding simulation in virtual surgery to improve the visual realism while meeting real-time performance and physical properties. An innovative adaptive-particle-based algorithm is proposed, which combines the repulsive force and the biomechanical properties, to achieve both realistic and computational efficiency in bleeding simulation.
METHODS: This paper integrates three modules based on Lagrangian particle method to achieve high fidelity real-time bleeding simulation in virtual surgery. Stepless adaptive particle algorithm is proposed to change the mass (radius) based on the proportion of particle positions between the bleeding surface and the soft tissue, which improves the resolution of bleeding surface and reduces the computational complexity of internal particles. The particle repulsion is introduced to avoid volume distortion caused by permeation of adaptive particles during collision, meeting the requirement of mass conservation. The biomechanics of bleeding particles are explored through the improved smoothed particle hydrodynamics (SPH) algorithm solving the Navier-Stokes (N-S) equation to improve the realism of physical properties.
RESULTS AND CONCLUSIONS: Compared to traditional simulation, the method proposed in this paper performs smoother bleeding surface, especially when topological changes occur during suction operation. Through particle tracking curves, it is possible to visually read the stepless variations of particle radius with position in different regions. Bleeding simulation is suitable for the bleeding effect of various types of wounds, which is well applied in virtual surgical scenes.
PURPOSE: Real-time assessment of surgical margins is critical for favorable outcomes in cancer patients. The iKnife is a mass spectrometry device that has demonstrated potential for margin detection in cancer surgery. Previous studies have shown that using deep learning on iKnife data can facilitate real-time tissue characterization. However, none of the existing literature on the iKnife facilitate the use of publicly available, state-of-the-art pretrained networks or datasets that have been used in computer vision and other domains.
METHODS: In a new framework we call ImSpect, we convert 1D iKnife data, captured during basal cell carcinoma (BCC) surgery, into 2D images in order to capitalize on state-of-the-art image classification networks. We also use self-supervision to leverage large amounts of unlabeled, intraoperative data to accommodate the data requirements of these networks.
RESULTS: Through extensive ablation studies, we show that we can surpass previous benchmarks of margin evaluation in BCC surgery using iKnife data, achieving an area under the receiver operating characteristic curve (AUC) of 81%. We also depict the attention maps of the developed DL models to evaluate the biological relevance of the embedding space CONCLUSIONS: We propose a new method for characterizing tissue at the surgical margins, using mass spectrometry data from cancer surgery.
The present invention relates to compound brain nourishing liquid and a preparing method thereof. The compound brain nourishing liquid is prepared by adopting Chinese medicinal herbs such as thinleaf milkwort root, ganoderma, grassleaf sweetflag rhizome, etc. and animal bodies such as the vertebrae of dogs, the heads of ctenopharyngodon idellus, etc. to be steamed for a long time and filtering out dregs. The liquid can be directly drunk as well as can be drunk after being adding into soup and dishes. Because the compound brain nourishing liquid is rich in lecithin, unsaturated fatty acid, calcium, vitamin, etc., the compound brain nourishing liquid has the functions of promoting the growth and the development of brain cells and conditioning the cerebrums, and the obvious effects of brain refreshment and brain invigoration can be generated. The present invention has a good mouth feel and does not have any side effect on human bodies.
Study participation will involve: (i) an intake survey; (ii) random assignment to the intervention or control group (this will be done in blocks of 4 households, to maintain balance in the intervention and control groups over the course of study enrollment); (iii) three in-home air quality monitoring deployments with the Home Health Box; (iv) three Home Health Reports (for those randomly assigned to the intervention group) generated from data the Home Health Box provides; and (v) a follow-up survey in a subset of intervention households to investigate the value and utility of the Home Health Report. The Home Health Report will provide quantitative information about health-relevant pollutants (fine particulate matter, carbon dioxide, nitrogen dioxide, and volatile organic compounds), their levels compared to health-based guidelines, their potential sources, as well as no- and low-cost actions occupants could take to improve indoor air quality. The Home Health Report will be designed to maximize utility to residents. Each Home Health Report will be provided within approximately three to four weeks after the corresponding Home Health Box has been received from the household. The second Home Health Box deployment will occur within several weeks to one month of the household receiving their first Home Health Report. The third and final Home Health Box deployment will occur within several weeks to one month of the household receiving their second Home Health. Households in the control group will also receive three Home Health Box deployments spaced approximately four to eight weeks apart, but will not receive Home Health Reports after the first and second deployments. At the close of their participation in the study, households in both the intervention and control groups will receive a comprehensive Home Health Report, including results from all three Home Health Box deployments and recommended actions occupants could take to improve their home air quality. In total, participation in this study will last between four to six months.
In various embodiments an appetite suppressant composition comprises at least one anorectic active ingredient (AAI); at least one of a nutritive substance, a controlled drug delivery agent (CDRA), and a cofactor; and optionally, an excipient. The AIA  may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The CDRA may comprise a cellulosic. The cofactor may comprise a chromium or selenium salt.  In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.
OBJECTIVES: Understanding the factors that lead to relapse is a major challenge for the clinical support of smoking cessation. Neurocognitive abilities such as attention, executive functioning and working memory, are possible predictors of relapse and can be easily assessed in everyday clinical practice. In this prospective longitudinal study, we investigated the relationship between pre-smoking cessation neurocognitive performance and relapse at six months in a sample of patients being treated for their tobacco dependence.
METHODS: 130 tobacco consumers were included in the study. They completed a comprehensive neuropsychological and clinical assessment before smoking cessation. The targeted abilities were intelligence, inhibition, shifting, working memory updating, verbal fluency and decision-making.
RESULTS: The rate of tobacco relapse at 6 months was 58%. Logistic regressions were used to assess which variables best explained relapse. None of the neuropsychological tests was a significant predictor of relapse at either 1, 3 or 6 months, either alone, or controlling for other covariates acting as significant predictors of relapse.
CONCLUSIONS: Common neuropsychological tests, even those specifically targeting executive functioning such as inhibition, are not useful predictors of the success of a smoking cessation program in a clinical setting. Other variables, such as motivation to quit smoking or the presence of comorbid depression or anxiety disorders, appear to be more useful predictors of relapse.
Currently, there is no way to measure how hard a doctor or midwife pulls when a baby is delivered. This device is a platform with special sensors. The doctor or midwife stands/sits on the platform while delivering the baby, and using a simple physical principle: for every action, there is an equal an opposite reaction. Prior to building the prototype and starting the study, the system and concept has been patented (US patent 6,684,165). In reality, this is not really a medical device since it does not touch the patient and does not have any effect on the delivery itself. It is merely a new type of external observation of the delivery of a baby that happens to produce useful information (the force that is exerted when the baby is delivered).
Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.
In patients taking alpha-blockers, do not initiate vardenafil therapy with STAXYN. Patients treated with alpha-blockers who have previously used vardenafil film-coated tablets may be changed to STAXYN at the advice of their healthcare provider. Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including STAXYN, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (for example, fainting). Consideration should be given to the following:

  * Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.
  * In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose. In patients taking alpha-blockers, do not initiate vardenafil therapy with STAXYN. Lower doses of vardenafil film-coated tablets should be used as initial therapy in these patients [see Dosage and Administration (2.4)]. 
  * In those patients already taking an optimized dose of PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increases in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitor.
  * Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs.
Milk replacers (MR) for calves contain alternative fat sources as substitute for milk fat. This substitution leads to differences in fat properties, such as the fatty acid profile and the triglyceride structure. This study evaluated how fat composition in MR affects gastrointestinal health, blood redox parameters, and postprandial metabolism in calves fed twice daily. Forty-five individually housed male Holstein-Friesian calves (2.3 ± 0.85 d of age) were assigned to 1 of 15 blocks based on the age and the day of arrival. Within each block, calves were randomly assigned to 1 of 3 experimental diets and received their respective diet from arrival until 35 d after arrival. The 3 experimental diets (n = 15 per treatment group) consisted of an MR with a blend of vegetable fats containing rapeseed and coconut (VG), an MR with only animal fats from lard and dairy cream (AN), and an MR containing a mixture of animal and vegetable fats including lard and coconut (MX). The fatty acid profile of each MR was formulated to resemble that of bovine milk fat while using only 2 fat sources. All MR were isoenergetic, with 30% fat (% DM), 24% crude protein, and 36% lactose. Chopped straw and water were available ad libitum from arrival onward but no starter feed was provided. Daily milk allowances were 6.0 L from d 1 to 5, 7.0 L from d 6 to 9, and 8.0 L from d 10 to 35, divided into 2 equal meals and prepared at 135 g/L (13.5% solids). Fecal appearance was scored daily; calves were weighed and blood was drawn on arrival and weekly thereafter. Urine and feces were collected over a 24-h period at wk 3 and 5 to determine apparent total-tract digestibility and assess gastrointestinal permeability using indigestible markers. Postprandial metabolism was evaluated at wk 4 by sequential blood sampling over 7.5 h, and the abomasal emptying rate was determined by acetaminophen appearance in blood. Fat composition in MR did not affect growth, MR intake, gastrointestinal permeability, nor nutrient digestibility. The percentage of calves with abnormal fecal scores was lower at wk 2 after arrival in calves fed VG than MX, whereas AN did not differ from the other treatments. Calves fed AN and MX had higher thiobarbituric acid reactive substances measured in serum than VG, whereas plasma ferric-reducing ability was greater in calves fed MX than VG. Postprandial acetaminophen concentrations did not differ across treatment groups, but the area under the curve was smaller in calves fed VG than in the other 2 treatments, which is indicative of a slower abomasal emptying. Postprandial serum triglyceride concentration was greater in calves fed AN than VG, whereas MX did not differ from the other treatments. Based on these outcomes, all 3 fat blends can be considered suitable for inclusion in MR for calves.